QualityStocksNewsBreaks Archives - Page 384 of 1452

WednesdayNov 02, 2022 11:51 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Doses First Patient in Global Berubicin Trial Evaluating GBM Treatment

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has provided an update on enrollment of its ongoing trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. The company announced that the first patient in Europe has been enrolled in the study and has started receiving dosages. Eventually the company plans to have 68 sites opened for the ongoing…

WednesdayNov 02, 2022 11:26 am

QualityStocksNewsBreaks – Hillcrest Energy Technologies Ltd. (CSE: HEAT) (OTCQB: HLRTF) (FRA: 7HIA.F) Names New CFO

Hillcrest Energy Technologies (CSE: HEAT) (OTCQB: HLRTF), a clean-technology company developing transformative power conversion technologies and control system solutions for next-generation EVs and electrical systems, has announced a new chief financial officer. The company has appointed seasoned veteran Samuel Yik as CFO; he will take over the position on Nov. 23, 2022. A chartered professional accountant with a diverse business background, Yik has garnered more than two decades of experience in the public sector, with more than a decade serving as CFO and managing publicly listed U.S. and Canadian companies. Yik is replacing Raj Clair, who will be leaving the…

WednesdayNov 02, 2022 10:32 am

QualityStocksNewsBreaks — Mullen Automotive Inc. (NASDAQ: MULN) Eliminates Some $13M in Debt

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, has eliminated $13 million in company debt, resulting in a reduction of overall indebtedness from more than $30 million last year to less than $10 million currently. The company has been working to strengthen its financial balance sheet; it also recently eliminated some $13 million of company debt associated with Esousa Holdings LLC. According to the announcement, MULN believes this debt conversion will save more than $3.5 million in interest expenses. With less than $10 million left of outstanding indebtedness, Mullen is maintaining its strong financial health. “It’s been a…

TuesdayNov 01, 2022 1:58 pm

QualityStocksNewsBreaks – CubCrafters Inc. Accelerates Manufacturing on High Demand Despite Supply Chain Challenges

CubCrafters, the leading designer and manufacturer of light-sport, experimental and Part 23 certified backcountry aircraft, has started a takeoff roll toward blue skies that offer the potential promise of corporate development through public investment. “It announced in July that it is taking reservations from potential investors as it awaits qualification by the U.S. Securities and Exchange Commission (‘SEC’) for a public stock listing. This news was met by immediate enthusiasm from the investment community as evidence of the expectations of the backcountry aircraft market’s continued growth,” a recent article reads. In a recent interview with The Bell2Bell Podcast, CubCrafters Vice…

TuesdayNov 01, 2022 1:34 pm

QualityStocksNewsBreaks – Knightscope Inc. (NASDAQ: KSCP) Announces New Contracts, Indicative of Company’s Continued Reach

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots (“ASRs”), has announced five new contracts. The contracts are with companies across the United States from several different industries. According to the announcement, the companies include an Ohio-based global pharmaceutical manufacturer and distributor of medical and laboratory products, as well as a provider of performance and data solutions for healthcare facilities; two hotels — one in Tennessee and one in Washington state; a sports complex in New York; and a multifamily housing complex in Pennsylvania. The contracts call for Knightscope ASRs to patrol and provide surveillance for everything from parking lots…

TuesdayNov 01, 2022 1:23 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures IRB Approval for Human Clinical Nicotine Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced its receipt of independent review board (“IRB”) approval for human clinical nicotine study NIC-H22-1, and that human dosing will begin soon. The 36-person human pharmacokinetic (“pk”) randomized, double blinded, cross-over study will be conducted in current cigarette smokers, wherein each person will visit the laboratory to be dosed three times over a period of weeks. Only one oral nicotine pouch (either DehydraTECH-nicotine; On! brand manufactured by Altria; or Zyn brand manufactured by Swedish Match) will be administered during each visit and evaluated. Predetermined questionnaires for subjective…

TuesdayNov 01, 2022 12:56 pm

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Exec to Present at Neuropsychiatric & Psychedelics Drug Development Summit

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), will be participating in the 5th annual Neuropsychiatric & Psychedelics Drug Development Summit. The summit runs through Nov. 2, 2022, and is being held in Boston. Cybin director of neuropharmacology Amy Reichelt, PhD, will present during the event; her presentation, titled “CYB004 — Modifications to DMT to Enhance its Therapeutic Potential,” includes an overview of the preclinical data for CYB004, Cybin’s deuterated dimethyltryptamine (DMT) program and the advantages of deuteration on its therapeutic effect. Reichelt’s presentation will begin at 1:15 p.m. ET today.“I am delighted to be…

TuesdayNov 01, 2022 12:33 pm

QualityStocksNewsBreaks – Hillcrest Energy Technologies Ltd. (CSE: HEAT) (OTCQB: HLRTF) Engages IMS for Investor Communications Expertise

Hillcrest (CSE: HEAT) (OTCQB: HLRTF), a clean technology company developing transformative power conversion technologies and control system solutions for next-generation electrical systems, today announced that it has retained IMS Investor Relations (“IMS”) effective Oct. 1, 2022. According to the update, IMS will provide capital markets consulting, corporate communications and strategic investor outreach. “Hillcrest’s highly adaptive power conversion technology is at an exciting stage of growth and development, evidenced in part by our two recent strategic partnerships including a global tier 1 automotive supplier,” said Hillcrest Chief Executive Officer Don Currie. “IMS is a respected firm with proven sector experience, and…

TuesdayNov 01, 2022 10:41 am

QualityStocksNewsBreaks – Odyssey Health Inc. (ODYY) Files for Patent Protection on Novel Breath-Propelled Intranasal Brain-Drug Delivery Device

Odyssey Health (OTC: ODYY) has filed for United States and global patent protection on its novel breath-propelled, intranasal brain-drug delivery device (“Nasal Device”). As previously announced, Odyssey’s recently completed phase I study to treat concussion successfully used Odyssey’s Nasal Device and drug combination. “We were very pleased with the functionality and performance of the Nasal Device during the phase I study and its administration of Odyssey’s PRV-002 concussion drug,” said Michael Redmond, CEO of Odyssey. “The ability to get drugs for neurological conditions delivered directly into the brain rapidly at effective levels while simultaneously having less concern for side effects…

MondayOct 31, 2022 1:51 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Shows Superior Performance to Other Anthracyclines, Standards of Care for GBM

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical innovator staking out its own position within the competitive field of research, having already progressed to human trials evaluating its novel glioblastoma multiforme (“GBM”) solution, known as Berubicin (or WP744). “Berubicin is a patented doxorubicin (‘Dox’) analog – an anthracycline chemotherapy agent novel in its ability to cross the blood-brain barrier to target tumors directly. Tested against Dox in cancer cells, Berubicin showed a greater capacity to destroy or damage the cancers. In models evaluating intracranial gliomas, Berubicin showed a greater capacity to prolong life than temozolomide, another standard of care for GBM,”…

Site Search

Company Search

Category: QualityStocksNewsBreaks